![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer’s Depression Candidate Flops in Phase 3 Study
Pfizer’s Depression Candidate Flops in Phase 3 Study
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
December 30, 2015
Pfizer’s latest Phase 3 study of Pristiq, a treatment for major depressive disorder, failed to meet its primary objective of superiority versus placebo in a study evaluating the drug for children between the ages of 7 and 17.
It marks the second Phase 3 study for pediatric patients receiving Pristiq that did not demonstrate superior efficacy versus placebo. The studies are being conducted as part of a postmarketing commitment.
Pristiq was approved in 2008 for the treatment of major depressive disorder in adults.
Upcoming Events
-
21Oct